Get started
Author

Ivica Fucek

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells
2014 · Uwe Reusch, Carmen Burkhardt, et al. · mAbs · 163
PDF
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19 + tumor cells
2015 · Uwe Reusch, Johannes Duell, et al. · mAbs · 133
PDF
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
2016 · Uwe Reusch, Kimberly H. Harrington, et al. · Clinical Cancer Research · 90
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
2021 · Susanne Wingert, Uwe Reusch, et al. · mAbs · 70
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
2019 · Kristina Ellwanger, Uwe Reusch, et al. · mAbs · 66
PDF
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
2017 · Thorsten Gantke, Michael Weichel, et al. · Protein Engineering Design and Selection · 50
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies
2017 · Kristina Ellwanger, Uwe Reusch, et al. · Frontiers in Oncology · 36
PDF
Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma
2018 · Thorsten Ross, Uwe Reusch, et al. · Blood · 29
Abstract 593: Highly cytotoxic EGFR/CD16A TandAbs specifically recruit NK cells to potently kill various types of solid tumors
2016 · Kristina Ellwanger, Uwe Reusch, et al. · Cancer Research · 24
AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma.
2017 · Thorsten Gantke, Uwe Reusch, et al. · Journal of Clinical Oncology · 17
Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers
2022 · Uwe Reusch, Kristina Ellwanger, et al. · Antibodies · 14
PDF
Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma
2016 · Thorsten Gantke, Michael Weichel, et al. · Blood · 9
Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method
2023 · Thomas Müller, Carolin Tasser, et al. · mAbs · 8
PDF
Abstract 3522: Preclinical development of an anti-CD30/anti-CD16A bispecific tetravalent TandAb antibody for the treatment of Hodgkin lymphoma
2012 · Stefan H. Knackmuss, Uwe Reusch, et al. · Cancer Research · 8
AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma
2017 · Thorsten Gantke, Uwe Reusch, et al. · Blood · 7
Abstract 5659: AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies
2020 · Uwe Reusch, Michael Damrat, et al. · Cancer Research · 6
Abstract 5671: AFM26 - A novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma
2017 · Thorsten Gantke, Uwe Reusch, et al. · Cancer Research · 5
EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies.
2017 · Anne Kerber, Michael Kluge, et al. · Journal of Clinical Oncology · 4
Construction and characterization of novel CD33/CD3 tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia (AML).
2015 · Uwe Reusch, Kimberly H. Harrington, et al. · Journal of Clinical Oncology · 3
Preclinical development, primary and secondary phrmacodynamics, of the CD19/CD3 Tandab (AFM11).
2014 · Eugene Zhukovsky, Stefan Knackmuss, et al. · Journal of Clinical Oncology · 2
AFM11, a CD19/CD3 bispecific tandab, to facilitate T-cell-mediated killing of CD19+ cells.
2013 · Eugene Zhukovsky, Uwe Reusch, et al. · Journal of Clinical Oncology · 2
High affinity CD3 RECRUIT TandAb for T cell-mediated lysis of CD19+ tumor B cells.
2012 · Eugene Zhukovsky, Uwe Reusch, et al. · Journal of Clinical Oncology · 2
Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30 + Malignancies
2021 · Uwe Reusch, Kristina Ellwanger, et al. · Blood · 1
Abstract 3753: Identification of antibodies against a novel tumor-associated MHC/peptide-target and generation of highly specific and potent HLA-A*02MMP1-003/CD3 TandAbs
2017 · Toni Weinschenk, Erich Rajkovic, et al. · Cancer Research · 1
Abstract 580: Anti-EGFRvIII TandAbs recruiting either T or NK cells are highly specific and potent therapeutic antibody candidates for the treatment of EGFRvIII+ tumors
2016 · Kristina Ellwanger, Uwe Reusch, et al. · Cancer Research · 1
Works count: 46
Citation count: 755
H-index: 11
I10-index: 11
Year
Topic
Type